Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02352896 · ClinicalTrials.gov registry record · Phase 2
Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome
A Phase 2 study, sponsored by PTC Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT02352896: Completed Phase 2 study, sponsored by PTC Therapeutics.
NCT02352896 is a Phase 2 study that has completed, run by PTC Therapeutics. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02352896, a Phase 2 study, has completed, sponsored by PTC Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
EPI-743 in Leigh syndrome participants that participated in previous EPI743-12-002 (NCT01721733) study.
Primary Outcome
NPMDS is a validated scale to assess the mitochondrial disease progression.
Interventions
- DRUG EPI-743
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-01-31 |
| Est. Completion | 2023-10-30 |
| Phase | Phase 2 |
What the finished NCT02352896 record still lists
NCT02352896 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 1 intervention - of which EPI-743 is the first listed.
NCT02352896 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02352896 about?
NCT02352896 is a clinical study titled "Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome". EPI-743 in Leigh syndrome participants that participated in previous EPI743-12-002 (NCT01721733) study.
What is the current status of trial NCT02352896?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2014-01-31. Estimated completion is 2023-10-30.
What interventions are being tested in trial NCT02352896?
The interventions under investigation include: EPI-743 (DRUG).
Who is sponsoring clinical trial NCT02352896?
This trial is sponsored by PTC Therapeutics, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02352896's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI